BidaskClub downgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning, BidAskClub reports.

Several other equities analysts also recently weighed in on the stock. Benchmark reiterated a buy rating on shares of Gray Television in a research note on Thursday, May 9th. Laidlaw set a $18.00 target price on shares of Flexion Therapeutics and gave the stock a buy rating in a research note on Thursday, April 11th. ValuEngine downgraded shares of Verso from a hold rating to a sell rating in a research note on Thursday, May 23rd. Wells Fargo & Co reiterated a buy rating on shares of Flexion Therapeutics in a research note on Wednesday, April 10th. Finally, Raymond James reiterated a buy rating on shares of Flexion Therapeutics in a research note on Thursday, March 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $23.71.

FLXN opened at $10.79 on Tuesday. The stock has a market capitalization of $409.91 million, a P/E ratio of -2.40 and a beta of 1.41. The company has a debt-to-equity ratio of 2.10, a current ratio of 6.32 and a quick ratio of 6.06. The stock has a 50-day simple moving average of $11.52. Flexion Therapeutics has a twelve month low of $9.65 and a twelve month high of $27.84.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.04. The firm had revenue of $10.56 million during the quarter, compared to the consensus estimate of $11.10 million. Flexion Therapeutics had a negative net margin of 549.07% and a negative return on equity of 131.94%. On average, research analysts expect that Flexion Therapeutics will post -4.07 earnings per share for the current year.

In other news, CFO David Arkowitz acquired 4,000 shares of Flexion Therapeutics stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average price of $11.99 per share, with a total value of $47,960.00. Following the completion of the purchase, the chief financial officer now owns 86,924 shares in the company, valued at $1,042,218.76. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael D. Clayman acquired 4,012 shares of Flexion Therapeutics stock in a transaction that occurred on Friday, May 10th. The shares were purchased at an average cost of $12.48 per share, with a total value of $50,069.76. Following the purchase, the insider now owns 74,868 shares of the company’s stock, valued at approximately $934,352.64. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 18,512 shares of company stock valued at $226,775. 16.01% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. Redmile Group LLC grew its stake in Flexion Therapeutics by 63.1% during the first quarter. Redmile Group LLC now owns 21,630 shares of the specialty pharmaceutical company’s stock valued at $270,000 after acquiring an additional 8,370 shares in the last quarter. Gagnon Securities LLC grew its stake in Flexion Therapeutics by 171.2% during the first quarter. Gagnon Securities LLC now owns 688,271 shares of the specialty pharmaceutical company’s stock valued at $8,590,000 after acquiring an additional 434,448 shares in the last quarter. Gagnon Advisors LLC grew its stake in Flexion Therapeutics by 89.6% during the first quarter. Gagnon Advisors LLC now owns 401,648 shares of the specialty pharmaceutical company’s stock valued at $5,013,000 after acquiring an additional 189,860 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Flexion Therapeutics by 22.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 15,300 shares of the specialty pharmaceutical company’s stock valued at $343,000 after acquiring an additional 2,800 shares in the last quarter. Finally, Claro Advisors LLC grew its stake in Flexion Therapeutics by 33.0% during the first quarter. Claro Advisors LLC now owns 22,150 shares of the specialty pharmaceutical company’s stock valued at $276,000 after acquiring an additional 5,500 shares in the last quarter. 89.88% of the stock is owned by institutional investors.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

See Also: What is a stock split?

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.